

References

1. Fineberg NA, Pellegrini L, Wellsted D, et al. Facing the “New Normal”: How Adjusting to the Easing of COVID-19 Lockdown Restrictions Exposes Mental Health Inequalities. *J Psychiatr Res*. 2021. doi:10.2139/ssrn.3813161
2. Uddin LQ. Cognitive and behavioural flexibility: neural mechanisms and clinical considerations. *Nat Rev Neurosci*. 2021;22(3):167-179. doi:10.1038/s41583-021-00428-w
3. Hollocks MJ, Charman T, Baird G, Lord C, Pickles A, Simonoff E. Exploring the impact of adolescent cognitive inflexibility on emotional and behavioural problems experienced by autistic adults. *Autism*. 2022;26(5):1229-1241. doi:10.1177/13623613211046160
4. Ozsivadjian A, Hollocks MJ, Magiati I, Happé F, Baird G, Absoud M. Is cognitive inflexibility a missing link? The role of cognitive inflexibility, alexithymia and intolerance of uncertainty in externalising and internalising behaviours in young people with autism spectrum disorder. *J Child Psychol Psychiatry Allied Discip*. 2021;62(6):715-724. doi:10.1111/jcpp.13295
5. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. Washington D.C.; 2013.
6. Reddihough DS, Marraffa C, Mouti A, et al. Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents with Autism Spectrum Disorders: A Randomized Clinical Trial. *JAMA - J Am Med Assoc*. 2019;322(16):1561-1569. doi:10.1001/JAMA.2019.14685
7. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. *Neuropsychopharmacology*. 2005;30(3):582-589. doi:10.1038/sj.npp.1300627
8. Zhou MS, Nasir M, Farhat LC, Kook M, Artukoglu BB, Bloch MH. Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. *J Am Acad Child Adolesc Psychiatry*. 2021;60(1):35-45. doi:10.1016/j.jaac.2020.03.007
9. McDougle CJ, Naylor S, Cohen D, Volkmar FR, Heniger G, Price L. A Double-blind, Placebo-controlled study of Fluvoxamine in Adults With Autistic Disorder. *Arch Gen Psychiatry*. 1996;53:1001-1008.
10. Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders. *J Am Acad Child Adolesc Psychiatry*. 2005;44(4):343-348. doi:10.1097/01.chi.0000153229.80215.a0
11. Owley T, Brune CW, Salt J, et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. *Autism Res*. 2010;3(1):1-7. doi:10.1002/aur.109
12. McCracken JT, McGough J, Shah B, et al. Risperidone in Children with Autism and Serious Behavioral Problems. *N Engl J Med*. 2002;347(5):314-321. doi:10.1056/nejmoa013171
13. Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. *Cochrane Database Syst Rev*. 2007;(1). doi:10.1002/14651858.CD005040.pub2
14. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. *Pediatrics*. 2009;124(6):1533-1540. doi:10.1542/peds.2008-3782
15. Marcus RN, Owen R, Kamen L, et al. A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic

- Disorder. *J Am Acad Child Adolesc Psychiatry*. 2009;48(11):1110-1119. doi:10.1097/CHI.0b013e3181b76658
16. Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). *Cochrane Database Syst Rev*. 2016;2016(6). doi:10.1002/14651858.CD009043.pub3
 17. Loebel A, Brams M, Goldman RS, et al. Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. *J Autism Dev Disord*. 2016;46(4):1153-1163. doi:10.1007/s10803-015-2628-x
 18. Fallah M, Shaikh M, Neupane B, Rusiecki D, Bennett T, Beyene J. Atypical Antipsychotics for Irritability in Pediatric Autism: A Systematic Review and Network Meta-Analysis. *J Child Adolesc Psychopharmacol*. 2019;29(3):168-180.
 19. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. *Int J Neuropsychopharmacol*. 2006;9(2):209-213. doi:10.1017/S1461145705005791
 20. Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. *Neuropsychopharmacology*. 2010;35(4):990-998. doi:10.1038/npp.2009.202
 21. Hirota T, Veenstra-Vanderweele J, Hollander E, Kishi T. Antiepileptic medications in autism spectrum disorder: A systematic review and meta-analysis. *J Autism Dev Disord*. 2014;44(4):948-957. doi:10.1007/s10803-013-1952-2
 22. Limbu B, Deb S, Roy M, Lee R, Roy A, Taiwo O. Randomised controlled trials of mood stabilisers for people with autism spectrum disorder: systematic review and meta-analysis. *BJPsych Open*. 2022;8(2):1-12. doi:10.1192/bjo.2022.18
 23. Hellings JA, Weckbaugh M, Nickel EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. *J Child Adolesc Psychopharmacol*. 2005;15(4):682-692. doi:10.1089/cap.2005.15.682
 24. Belsito K, Law P, Kirk K, Landa R, Zimmerman A. Lamotrigine Therapy for Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. *J Autism Dev Disord*. 2001;31(2):175-181.
<http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed5&NEWS=N&AN=2003496113>.
 25. Wasserman S, Iyengar R, Chaplin W, et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. *Int Clin Psychopharmacol*. 2006;21(6):363-367.
 26. Ghuman J, Aman M, Lecavalier L, et al. Randomized, Placebo-Controlled, Crossover Study of Methylphenidate for Attention-Deficit/Hyperactivity Disorder Symptoms in Preschoolers with Developmental Disorders. *J Child Adolesc Psychopharmacol*. 2009;19(4):329-339.
 27. Handen BL, Johnson CR, Lubetsky MJ. Efficacy of methylphenidate among children with autism and ADHD. *J Autism Dev Disord*. 2001;30(3):245-255.
 28. Jahromi LB, Kasari CL, McCracken JT, et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. *J Autism Dev Disord*. 2009;39(3):395-404. doi:10.1007/s10803-008-0636-9
 29. Sturman N, Deckx L, van Driel ML. Methylphenidate for children and adolescents with autism spectrum disorder. *Cochrane Database Syst Rev*. 2017;2017(11). doi:10.1002/14651858.CD011144.pub2

30. Rodrigues R, Lai MC, Beswick A, et al. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. *J Child Psychol Psychiatry Allied Discip.* 2021;62(6):680-700. doi:10.1111/jcpp.13305
31. Politte LC, Scahill L, Figueroa J, McCracken JT, King B, McDougle CJ. A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: An analysis of secondary outcome measures. *Neuropsychopharmacology.* 2018;43(8):1772-1778. doi:10.1038/s41386-018-0039-3
32. Scahill L, McCracken JT, King BH, et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. *Am J Psychiatry.* 2015;172(12):1197-1206. doi:10.1176/appi.ajp.2015.15010055
33. Posey D, Puntney J, Sasher T, Kem DL, Mcdougle CJ. Guanfacine Treatment of Hyperactivity and Inattention in Pervasive Developmental Disorders: A Retrospective Analysis of 80 Cases. *J Child Adolesc Psychopharmacol.* 2004;14(2):233-241.
34. Jaselskis C, Cook E, Fletcher K, Leventhal B. Clonidine Treatment of Hyperactive and Impulsive Children with Autistic Disorder. *J Clin Psychopharmacol.* 1992;12(5).
35. Fankhauser M, Karumanchi V, German M, Yatse A, Karumanchi S. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. *J Clin Psychiatry.* 1992;53(3):77-82.
36. Hardan A, Hendren R, Aman M, et al. Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies. *Autism.* 2019;23(8):2096-2111.
37. Aman MG, Findling RL, Hardan AY, et al. Safety and efficacy of memantine in children with autism: Randomized, placebo-controlled study and open-label extension. *J Child Adolesc Psychopharmacol.* 2017;27(5):403-412. doi:10.1089/cap.2015.0146
38. Brignell A, Prakash C, Marraffa C, Williams K, May T. Memantine for autism spectrum disorder. *Cochrane Database Syst Rev.* 2021;2021(1). doi:10.1002/14651858.CD013845
39. Soorya LV, Fogg L, Ocampo E, et al. Neurocognitive Outcomes from Memantine: A Pilot, Double-Blind, Placebo-Controlled Trial in Children with Autism Spectrum Disorder. *J Child Adolesc Psychopharmacol.* 2021;31(7):475-484. doi:10.1089/cap.2021.0010
40. Woodard C, Groden J, Goodwin M, Bodfish J. A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism. *Autism.* 2007;11(1):29-41. doi:10.1177/1362361307070989
41. Veenstra-Vanderweele J, Cook EH, King BH, et al. Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial. *Neuropsychopharmacology.* 2017;42(7):1390-1398. doi:10.1038/npp.2016.237
42. Erickson CA, Veenstra-Vanderweele JM, Melmed RD, et al. STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study. *J Autism Dev Disord.* 2014;44(4):958-964. doi:10.1007/s10803-013-1963-z
43. Hardan A, Fung L, Libove R, et al. A Randomized Controlled Pilot Trial of Oral N-Acetylcysteine in Children with Autism. *Biol Psychiatry.* 2012;71(11):956-961. doi:10.1016/j.biopsych.2012.01.014.A
44. Wink LK, Adams R, Wang Z, et al. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. *Mol Autism.* 2016;7(1):1-9. doi:10.1186/s13229-016-0088-6

45. Dean OM, Gray KM, Villagonzalo KA, et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N -acetyl cysteine in children with autistic disorder. *Aust N Z J Psychiatry*. 2017;51(3):241-249. doi:10.1177/0004867416652735
46. Lee TM, Lee KM, Lee CY, Lee HC, Tam KW, Loh EW. Effectiveness of N-acetylcysteine in autism spectrum disorders: A meta-analysis of randomized controlled trials. *Aust N Z J Psychiatry*. 2021;55(2):196-206. doi:10.1177/0004867420952540
47. Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and asperger's disorders. *Neuropsychopharmacology*. 2003;28(1):193-198. doi:10.1038/sj.npp.1300021
48. Hollander E, Bartz J, Chaplin W, et al. Oxytocin Increases Retention of Social Cognition in Autism. *Biol Psychiatry*. 2007;61:498-503. doi:10.1016/j.biopsych.2006.05.030
49. Anagnostou E, Soorya L, Chaplin W, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders : a randomized controlled trial. *Mol Autism*. 2012;3(16):1-9. doi:10.1186/2040-2392-3-16
50. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal Oxytocin Improves Emotion Recognition for Youth with Autism Spectrum Disorders. *Biol Psychiatry*. 2010;67(7):692-694. doi:10.1016/j.biopsych.2009.09.020
51. Sikich L, Kolevzon A, King BH, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. *N Engl J Med*. 2021;385(16):1462-1473. doi:10.1056/nejmoa2103583
52. Hollander E, Jacob S, Jou R, et al. Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. 2022;79(8):760-769. doi:10.1001/jamapsychiatry.2022.1717
53. Jacob S, Veenstra-VanderWeele J, Murphy D, et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. *The Lancet Psychiatry*. 2022;9(3):199-210. doi:10.1016/S2215-0366(21)00429-6
54. Bolognani F, Del Valle Rubido M, Squassante L, et al. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. *Sci Transl Med*. 2019;11(491):1-15. doi:10.1126/scitranslmed.aat7838
55. Parker KJ, Oztan O, Libove RA, et al. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. *Sci Transl Med*. 2019;11(491). doi:10.1126/scitranslmed.aau7356.A
56. Hollander E, Uzunova G, Taylor BP, et al. Randomized crossover feasibility trial of helminthic *Trichuris suis* ova versus placebo for repetitive behaviors in adult autism spectrum disorder. *World J Biol Psychiatry*. 2020;21(4):291-299. doi:10.1080/15622975.2018.1523561
57. Graat I, Balke S, Prinssen J, et al. Effectiveness and safety of deep brain stimulation for patients with refractory obsessive compulsive disorder and comorbid autism spectrum disorder; A case series. *J Affect Disord*. 2022;299(December 2021):492-497. doi:10.1016/j.jad.2021.12.089
58. Ameis SH, Blumberger DM, Croarkin PE, et al. Treatment of Executive Function Deficits in autism spectrum disorder with repetitive transcranial magnetic stimulation: A double-blind, sham-controlled, pilot trial. *Brain Stimul*. 2020;13(3):539-547. doi:10.1016/j.brs.2020.01.007

59. Kang JN, Song JJ, Casanova MF, Sokhadze EM, Li XL. Effects of repetitive transcranial magnetic stimulation on children with low-function autism. *CNS Neurosci Ther.* 2019;25(11):1254-1261. doi:10.1111/cns.13150
60. Casanova MF, Shaban M, Ghazal M, et al. Effects of transcranial magnetic stimulation therapy on evoked and induced gamma oscillations in children with autism spectrum disorder. *Brain Sci.* 2020;10(7):1-19. doi:10.3390/brainsci10070423
61. Smith JR, Disalvo M, Green A, Ceranoglu TA. Treatment Response of Transcranial Magnetic Stimulation in Intellectually Capable Youth and Young Adults with Autism Spectrum Disorder : A Systematic Review and Meta - Analysis. *Neuropsychol Rev.* 2022;(0123456789). doi:10.1007/s11065-022-09564-1
62. Barahona-Corrêa JB, Velosa A, Chainho A, Lopes R, Oliveira-Maia AJ. Repetitive Transcranial Magnetic Stimulation for Treatment of Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. *Front Integr Neurosci.* 2018;12(July). doi:10.3389/fnint.2018.00027
63. Enticott PG, Fitzgibbon BM, Kennedy HA, et al. A double-blind, randomized trial of deep Repetitive Transcranial Magnetic Stimulation (rTMS) for autism spectrum disorder. *Brain Stimul.* 2014;7(2):206-211. doi:10.1016/j.brs.2013.10.004
64. Avirame K, Stehberg J, Todder D. Enhanced cognition and emotional recognition, and reduced obsessive compulsive symptoms in two adults with high-functioning autism as a result of deep Transcranial Magnetic Stimulation (dTMS): a case report. *Neurocase.* 2017;23(3-4):187-192. doi:10.1080/13554794.2017.1361451
65. Nezgovorova V, Ferretti CJ, Taylor BP, et al. Potential of cannabinoids as treatments for autism spectrum disorders. *J Psychiatr Res.* 2021;137(February):194-201. doi:10.1016/j.jpsychires.2021.02.048
66. Hollander E, Hagerman RJ, Ferretti CJ, eds. *Textbook of Autism Spectrum Disorders.* 2nd ed. Washington D.C.: American Psychiatric Association Publishing; 2022.
67. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder. *Am Psychiatr Assoc.* 2007.
68. Wolters LH, de Haan E, Hogendoorn SM, Boer F, Prins PJM. Severe pediatric obsessive compulsive disorder and co-morbid autistic symptoms: Effectiveness of cognitive behavioral therapy. *J Obsessive Compuls Relat Disord.* 2016;10:69-77. doi:10.1016/j.jocrd.2016.06.002
69. Murray K, Jassi A, Mataix-Cols D, Barrow F, Krebs G. Outcomes of cognitive behaviour therapy for obsessive-compulsive disorder in young people with and without autism spectrum disorders: A case controlled study. *Psychiatry Res.* 2015;228(1):8-13. doi:10.1016/j.psychres.2015.03.012
70. Vause T, Jaksic H, Neil N, Frijters JC, Jackiewicz G, Feldman M. Functional Behavior-Based Cognitive-Behavioral Therapy for Obsessive Compulsive Behavior in Children with Autism Spectrum Disorder: A Randomized Controlled Trial. *J Autism Dev Disord.* 2020;50(7):2375-2388. doi:10.1007/s10803-018-3772-x
71. Wickberg F, Lenhard F, Aspvall K, et al. Feasibility of internet-delivered cognitive-behavior therapy for obsessive-compulsive disorder in youth with autism spectrum disorder: A clinical benchmark study. *Internet Interv.* 2022;28(February). doi:10.1016/j.invent.2022.100520
72. Jassi A, Fernández de la Cruz L, Russell A, Krebs G. An Evaluation of a New Autism-Adapted Cognitive Behaviour Therapy Manual for Adolescents with Obsessive-

- Compulsive Disorder. *Child Psychiatry Hum Dev*. 2021;52(5):916-927. doi:10.1007/s10578-020-01066-6
73. Farrell L, Waters A, Milliner E, Ollendick T. Comorbidity and treatment response in pediatric obsessive-compulsive disorder: A pilot study of group cognitive-behavioral treatment. *Psychiatry Res*. 2012;199(2):115-123. doi:10.1016/j.psychres.2012.04.035
 74. Iniesta-Sepúlveda M, Nadeau JM, Ramos A, Kay B, Riemann BC, Storch EA. An Initial Case Series of Intensive Cognitive–Behavioral Therapy for Obsessive–Compulsive Disorder in Adolescents with Autism Spectrum Disorder. *Child Psychiatry Hum Dev*. 2018;49(1):9-19. doi:10.1007/s10578-017-0724-1
 75. Choque Olsson N, Flygare O, Coco C, et al. Social Skills Training for Children and Adolescents With Autism Spectrum Disorder: A Randomized Controlled Trial. *J Am Acad Child Adolesc Psychiatry*. 2017;56(7):585-592. doi:10.1016/j.jaac.2017.05.001
 76. Gates JA, Kang E, Lerner MD. Efficacy of group social skills interventions for youth with autism spectrum disorder: A systematic review and meta-analysis. *Clin Psychol Rev*. 2017;52:164-181. doi:10.1016/j.cpr.2017.01.006
 77. Pahnke J, Hirvikoski T, Bjureberg J, et al. Acceptance and commitment therapy for autistic adults: An open pilot study in a psychiatric outpatient context. *J Context Behav Sci*. 2019;13:34-41. doi:10.1016/j.jcbs.2019.04.002
 78. Ritschel LA, Guy L, Maddox BB. A pilot study of dialectical behaviour therapy skills training for autistic adults. *Behav Cogn Psychother*. 2022;50(2):187-202. doi:10.1017/S1352465821000370
 79. Bemmouna D, Coutelle R, Weibel S, Weiner L. Feasibility, Acceptability and Preliminary Efficacy of Dialectical Behavior Therapy for Autistic Adults without Intellectual Disability: A Mixed Methods Study. *J Autism Dev Disord*. 2021;(0123456789). doi:10.1007/s10803-021-05317-w
 80. Hartley M, Dorstyn D, Due C. Mindfulness for Children and Adults with Autism Spectrum Disorder and Their Caregivers: A Meta-analysis. *J Autism Dev Disord*. 2019;49(10):4306-4319. doi:10.1007/s10803-019-04145-3
 81. Neece CL. Mindfulness-based stress reduction for parents of young children with developmental delays: Implications for parental mental health and child behavior problems. *J Appl Res Intellect Disabil*. 2014;27(2):174-186. doi:10.1111/jar.12064
 82. Spek AA, van Ham NC, Nyklíček I. Mindfulness-based therapy in adults with an autism spectrum disorder: A randomized controlled trial. *Res Dev Disabil*. 2013;34(1):246-253. doi:10.1016/j.ridd.2012.08.009
 83. Dandil Y, Smith K, Kinnaird E, Toloza C, Tchanturia K. Cognitive Remediation Interventions in Autism Spectrum Condition: A Systematic Review. *Front Psychiatry*. 2020;11(July). doi:10.3389/fpsy.2020.00722
 84. Hajri M, Abbes Z, Yahia H Ben, et al. Cognitive deficits in children with autism spectrum disorders: Toward an integrative approach combining social and non-social cognition. *Front Psychiatry*. 2022;13(1). doi:10.3389/fpsy.2022.917121
 85. Duncan A, Liddle M, Stark LJ. Iterative Development of a Daily Living Skills Intervention for Adolescents with Autism Without an Intellectual Disability. *Clin Child Fam Psychol Rev*. 2021;24(4):744-764. doi:10.1007/s10567-021-00360-6
 86. Duncan A, Meinzen-Derr J, Ruble LA, Fassler C, Stark LJ. A Pilot Randomized Controlled Trial of a Daily Living Skills Intervention for Adolescents with Autism. *J Autism Dev Disord*. 2022;52(2):938-949. doi:10.1007/s10803-021-04993-y

87. Preas EJ, Mathews TL. Evaluation of Caregiver Training Procedures to Teach Activities of Daily Living Skills. *Behav Anal Pract.* 2021;14(4):958-973. doi:10.1007/s40617-020-00513-z
88. Weaver L. Effectiveness of Work, Activities of Daily Living, Education, and Sleep Interventions for People with Autism Spectrum Disorder: A Systematic Review. *Am J Occup Ther.* 2015;69(5).
89. Khalifa G, Sharif Z, Sultan M, Di Rezze B. Workplace accommodations for adults with autism spectrum disorder: a scoping review. *Disabil Rehabil.* 2020;42(9):1316-1331. doi:10.1080/09638288.2018.1527952
90. Hedley D, Uljarević M, Cameron L, Halder S, Richdale A, Dissanayake C. Employment programmes and interventions targeting adults with autism spectrum disorder: A systematic review of the literature. *Autism.* 2017;21(8):929-941. doi:10.1177/1362361316661855
91. Lopata C, Thomeer ML, Rodgers JD, Donnelly JP, Booth AJ. RCT of a Comprehensive Outpatient Treatment for Children with Autism Spectrum Disorder. *J Clin Child Adolesc Psychol.* 2020;50(6):1-15. doi:10.1080/15374416.2020.1790380
92. Shaffer RC, Schmitt LM, Reisinger DL, et al. Regulating Together: Emotion Dysregulation Group Treatment for ASD Youth and Their Caregivers. *J Autism Dev Disord.* 2022;(0123456789). doi:10.1007/s10803-022-05461-x
93. McNellis CA, Harris T. Residential Treatment of Serious Behavioral Disturbance in Autism Spectrum Disorder and Intellectual Disability. *Child Adolesc Psychiatr Clin N Am.* 2014;23(1):111-124. doi:10.1016/j.chc.2013.08.005
94. Krauss MW, Seltzer MM, Jacobson HT. Adults with autism living at home or in non-family settings: Positive and negative aspects of residential status. *J Intellect Disabil Res.* 2005;49(2):111-124. doi:10.1111/j.1365-2788.2004.00599.x